Categories

Above the Fold

PHARMA: Crestor briefly revisited

It’s been a long while since anything was said about Crestor in this scandal sheet, but I noticed a report today that a Crestor patient died of severe muscle wasting. Crestor is the statin that The Lancet attacked so publicly at the end of 2003, and one of the overall questions about statins is their effect on muscle pain and wasting. Back in late 2003 I featured a short-selling group (Friedman, Billings, Ramsey Group) that was advising its clients to go short of Astra-Zeneca around $48 a share with a target of $40. Their basic argument was that Crestor wouldn’t do too well due to the safety concerns, and that A-Z would not see its expected returns from Crestor. Crestor has in fact seen somewhat weaker sales than originally expected, despite the weird TV commercial with Jean-Luc Picard/Patrick Stewart’s Shakespearian tones coming out of the doctor and patient’s mouths in iambic pentameter.

Well as this chart shows the stock hung out in that $45-50 range for most of 2004 until September. I don’t know if FBR was still short at that point, but since then there’s been a more than 20% decline in the stock, partly on Crestor, partly on the recent failure of its cancer drug Iressa, and partly because of the overall Vioxx negative-halo effect.

POLICY: Experts believe uninsured are a priority….but for whom?

The Commonwealth Fund has sponsored one of Harris Interactive’s periodic surveys of health care experts and influencers (and no they didn’t ask me what I thought!).

I have yet to dig into the survey but the experts believe that the most important priority for Congress is dealing with the uninsured. So it sounds to me as if either they asked the experts what they thought ought to be the main priority of the nation regarding health care or what they hoped to be the priority of the nation. Because this nation, or at least its government, seems to have a lot of priorities in spending its money at the moment and covering the uninsured does not make the list. Unless of course you’ve really bought into the kool-aid that Association Health Plans and tax credits for those on minimum wage are going to solve the problem.

POLICY: As I’ve always suspected, Health Care = Communism + Frappuccinos

Those of you who think I’m an unreconstructed commie will correctly suspect that I’ve always discussed Marxism in my health care talks. You’d be amazed at how many audiences of hospital administrators in the mid-west know nothing about the integral essentials of Marx’s theory of history. And I really enjoy bring the light to them, especially when I manage to reference Mongolia 1919, managed care and Communism in the same bullet point.

While I’ve always been very proud of that one (err.. maybe you have to be there, but you could always hire me to come tell it!), even if I am jesting, there’s a really loose use of the concept of Marxism in this piece called A Prescription for Marxism in Foreign Policy from (apparently) libertarian-leaning Harvard professor Kenneth Rogoff. He opens with this little nugget:

"Karl Marx may have suffered a second death at the end of the last century, but look for a spirited comeback in this one. The next great battle between socialism and capitalism will be waged over human health and life expectancy. As rich countries grow richer, and as healthcare technology continues to improve, people will spend ever growing shares of their income on living longer and healthier lives."

Actually he’s right that there will be a backlash against the (allegedly) market-based capitalism — which has actually been closer to all-out mercantilist booty capitalism — that we’re seen over the last couple of decades. History tends to be reactive and societies go through long periods of reaction to what’s been seen before. In fact the 1980-20?? (10-15?) period of "conservatism" is a reaction to the 1930-1980 period of social corporatism seen in most of the western world. And any period in which the inequality of wealth and income in one society continues to grow at the current rate will eventually invite a reaction–you can ask Louis XVI of France about that.

But when Rogoff is talking about Marxism in health care what he really means is that, because health care by definition will consume more and more of our societal resources, the arguments about the creation and distribution of health care products and services will look more like the arguments seen in the debates about how the government used to allocate resources for "guns versus butter" in the 1950s. These days we are supposed to believe that government blindly accepts letting "the market" rule, even if for vast sways of the economy the government clearly rules the market, which in turn means that those corporations with political influence set the rules and the budgets (quick now, it begins with an H…). That’s how defense has always been and how pharmaceuticals will increasingly be. Rogoff recognizes the centrality of this argument in his description of what’s wrong with American health care:

Part of the rise in U.S. healthcare costs stems from the breakdown of the checks and balances that more centralized systems provide. (For example, Americans are several times more likely to receive heart bypass surgery than Canadians, where the procedure is reserved for extreme cases. Yet several studies suggest that patients are no worse off in Canada than in the United States). And even the most fanatical free marketers recognize that healthcare is different from other markets, and that the standard supply-and-demand principles don’t necessarily apply. Consumers have poor information, and there is an obvious case for greater government involvement than in other markets.

But he then goes on to say that the much greater spending seen here as compared to Canada and the UK creates both a terrible service level (and by implication quality level) and diminishes innovation in health care services. And if all countries squeezed profits in the health sector the way Europe and Canada do, there would be much less global innovation in medical technology.

Today, the whole world benefits freely from advances in health technology that are driven largely by the allure of the profitable U.S. market. If the United States joins other nations in having more socialized medicine, the current pace of technology improvements might well grind to a halt. Even as the status quo persists, I wonder how content Europeans and Canadians will remain as their healthcare needs become more expensive and diverse. There are already signs of growing dissatisfaction with the quality of all but the most basic services. In Canada, the horrific delays for elective surgery remind one of waiting for a car in the old Soviet bloc. And despite British Chancellor Gordon Brown’s determined efforts to rebuild the country’s scandalously dilapidated public hospital system, anyone who can afford to go elsewhere usually does.

His conclusion is that because for the sake of social equity government intervention in the system is warranted, the health sector will be a "battleground" between capitalism and socialism through this century. If you get past his mis-use or mis-understanding of the terms "capitalism" and "socialism", the point he’s making is quite interesting. It does though suffer from a typically Amero-centric bias. Rogoff assumes that the extra spending on health care in America leads to better services and by implication better quality. But that’s an old chestnut. By that measure the higher spending in Canada (11% of GDP) should lead to a better system than in France (9%) or Germany (10%). But in those two nations access to drugs and technology is much greater than in the UK or Canada, and things like waiting times are comparable to the US — in fact in Australia and New Zealand they’re better than they are here. A few years back The Economist said that the Swiss system (again several percentage points cheaper than here) was better than the American on an absolute level. Furthermore recent studies of international care quality suggest that particularly for primary care, the US is results-wise(at best) in the middle of the pack. All of those nations have a heavier proportion of government funding of health care spending than in the US, and all of them spend a whole lot less money. Note that the US government spends more per head (and damn nearly as much as share of GDP) on health care as the whole of the UK.

So that all tells us one thing. We’re paying a lot more for health care here, but it isn’t necessarily getting us better outcomes, innovation or even services. We might though have nicer waiting rooms and we certainly lead the league in surgeons with Porsche 911s. Therefore it’s a stretch to imply that higher private spending leads directly to innovation and better services, particularly if the system is not set up with either government-based or real market-based co-ercive capabilities to promote efficiency and value for money. And lets be real, the US system is set up to provide revenues and profits for providers and suppliers. It’s a bit like saying Tammany Hall provided the best government services because it cost the most, when huge chunks of the money were getting diverted off into corruption.

Furthermore, it’s also a stretch for Rogoff to suggest that by definition government spending creates lower innovation compared to private spending. After all government spending led to the creation of the Internet and biotechnology. Private spending created reality TV. And despite the fact that there is no private spending on defense, well the boys and girls in the US military are no longer riding around on horses pulling gun carts. Somehow innovation and progress seems to find a way to happen even in government sponsored sectors. And if we want to drag real communists into the equation, the reason that we’re not all speaking German is that Hitler lost WWII to a nation that ten years before he invaded was inhabited by peasants. Yup, unpleasant as it might have been, Stalin’s Great Leap Forward in the 1930s was by far the fastest period of economic growth seen in any nation, probably any time…..just in time to save our arses in 1942-4.

I’m not exactly advocating purges, slave labor camps, collectivization and enforced Ten Year Plans as a panacea for the future of health care (although David Brailer keeps going on about his ten year plan). But the overall point is that greater government involvement in spending and regulation of health care doesn’t necessarily mean the disaster in services and innovation that Rogoff suggests. And there are excellent reasons from the "socialist" angle for greater government involvement in health care than we have now.

The first is the fallacy that there can be such a thing as a private health insurance market with free use of underwriting. Social insurance (or universal insurance), in which everyone pays in and everyone receives at least a basic level of benefits is the only way to get around the problem of the uninsured and the uninsurable. It of course means a relative redistribution of income from the healthy and wealthy to the poor and sick, but in fact that can be budget neutral to the healthy and wealthy if the overall price tag is kept down. That though would require a redistribution of income from the health care sector to the rest of society. Such universal insurance is good enough for everyone over-65 in this country and good enough for everyone else in the developed world, but the concept just can’t seem to get the attention of the American public enough to force it past the "special interests" in Congress. And everyone (apart from actuaries and underwriters and some participants in the system) suffers as a result.

The second is the role of government or someone like it as a clearinghouse of information or as a standards-setting body in a market where information access is very lopsided. Health care is very, very complex and someone has to provide decent information (preferably with some regulatory teeth) so that consumers/patients are not at the mercy of providers and suppliers who know far more than they do and in whom most patients still are forced to place their trust blindly. This is the role of the NICE in the UK, and in theory ought to be the role of the FDA here. Adding an economic element to that role by giving information on value for money would probably be derided as socialism by Rogoff’s "capitalists", but is a rational role for government. And one they are likely to add as spending increases — of course the Brits and Aussies already have done so to some extent, and are linking cost-effective performance to payment.

So overall I don’t think there’s any basis for suggesting that if we have more "socialism" in health care — and by that I’m using Rogoff’s meaning of government spending, regulation and income redistribution — we will necessarily have worse services or lower innovation. Although we may have lower drug prices and a less profitable health care industry. Anyone awake during the last three months of Vioxx breast-beating is becoming painfully aware that expensive "innovation" can be costly for the wrong reasons and actually not be innovative–COX-2s didn’t really do what they were supposed to do (reduce GI problems) but they did cost a lot more than NSAIDs in both money and increased heart disease. But it’s that kind of "innovation" that Rogoff correctly says that Americans are paying more for than anyone else.

However, Rogoff is making a very important point when he discusses the likely trade-offs between basic health care and lifestyle enhancements that will dominate the politics of health care for the next century. We’ve already seen this begin with the medicalization of social afflictions (ugly teeth, small breasts), the medicalization of several "diseases" that aren’t really diseases (impotence, shyness), and the medicalization of old age (osteoporosis, prostate cancer). Now the nano-gurus are discussing the medicalization of death — which will presumably lead to a cure, or at least a delay, for it at a hell of a price.

As more and more health care services become luxury goods, there is a justifiable discussion about what’s a basic necessity and what should someone have to pay for out of their discretionary income. At the moment no-one’s seriously suggesting that your boob job or teeth whitening should be other than an individual expense, or that your cancer treatment is a luxury good to be chosen if your mood and wallet fits. But clearly the middle of that continuum will continue to fill up.

This leads me to what has been called the mocha-Frappuchino problem. I read an article once (that I can’t find anymore) that discussed the increase in productivity of the US workforce since the 1930s. It’s doubled. Which means that we could work half the time and have a 1930s standard of living, or we could work as hard as we do now and have more stuff. The author noted that in the 1930s you couldn’t get a Mocha Frappuchino; so you’ve been spending Wednesday 1pm through Friday afternoon working for your Frappuchino (or similarly frothy goods and services).

We’ve always thought of health care as an "essential". And eventually even in the US I believe we’ll figure out a way to solve the problem of creating an equitable and sustainable social insurance model for that "essential". But increasingly, the health care Frappuccino will be paid for and delivered privately, in a separate system. Of course it’s the blurring of those two systems that concerns bleeding heart liberals like me, as that can well lead not as it has done here for the Medicare population, as society giving Frappuccinos to everyone, but instead society deciding to take away essential services from those who can’t afford Frappuccinos.

And that will be the real socialism versus capitalism battle of the next decades.

TECHNOLOGY: The BitTorrent Effect

The next really disruptive technology is already here, but most people don’t know about it. Torrents were mentioned at a health care IT conference I went to last June and no one there other than the geek presenting knew what they were. This article in Wired called The BitTorrent Effect explains. They’re essentially a way of sharing huge files relatively quickly between lots of people. Everyone downloading a file is also uploading parts of it. So the more people (or computers) sharing the file the faster you can download it. I’ve become an avid user of torrents to download soccer matches. It takes about 2-4 hours to download a game (around about a gig). I don’t know if there’s copyright on the games, but as they’re not being broadcast where I live, to me it’s the equivalent of someone else lending me a video tape of the game straight after it’s been shown. Hollywood is rightfully terrified that this will be a version of Napster, with people putting movies up on the web, others downloading them and DVD sales plummeting. But the Wired article suggests that there’s a much greater change going on, with the ability for virtually anyone to start developing their own content, and then to use the web for distribution.

I haven’t really figured out a health care angle on this yet other than moving very large files around asynchronously is probably of interest to radiologists. But like blogging software, and the web itself, this is another example of a fast-moving technology changing the way things are done and the way information is distributed. So continue to pay attention, and email me if you want to know how to access those soccer games!

HOSPITALS: Uncharitable?

I owe THCB readers a follow-up piece on King-Drew Medical Center and have had it in the queue since Christmas, but I’m crunched with other work and the blog pieces are suffering as a consequence. So meanwhile please go read this excellent piece from the New Republic’s Jonathan Cohn on charity care and whether hospitals are delivering enough: Uncharitable?

PHARMA: 3 Quickies

Following up on yesterdays forecast of issues for 2005, Melissa David in The Street.com has a good article about how the Merck Mess Shows FDA’s Flaws. The key takeaway is that the FDA has been fast-tracking drugs that aren’t really break-through, and approving them while the data is still being gathered. It seems likely both that the approval process will slow and that there’ll be much greater requirement for post-market surveillance. Meanwhile FDA renegade and now superstar David Graham has upped his estimate of the number of deaths from Vioxx from 28,000 up to between 88,000 and 139,000–if and when The Lancet publishes that number you can be assured that the trial lawyers will use it.

Secondly, the US pharmacopoeia is out with its list of drugs that Medicare ought to cover under the new Part D. This is a screaming big deal because it lumps several drugs that are in different competitive groups in the market in the same therapeutic class. For example, the biphosphonates Fosamax and Actonel are lumped in with two other drugs in the anti-osteoporosis class. So potentially an aggressive PBM may try to push its patients away from them onto an older and cheaper drug. Expect plenty more politics about this, but in a system where the government is making the rules, it’s rules like these that make and lose fortunes.

Finally, John Mack of the Pharma Marketing list serve and Pharma Marketing News has entered the murky world of blogging with his Pharma Marketing Blog. Welcome John.

2005 FORECAST: What to look out for this year

Given that at one point in my life I was a futurist and that I still claim to know something about forecasting, let me start 2005 at THCB by telling you what I think may be the big trends to look out for this year. I’m not going to necessarily tell you what the end results will be, but if you are interested in health care, and working on topics that matter to you and your organizations, these issues are where you may both see plenty of activity and also spend much of your time.

So in no particular order

FDA reform: Last years revelations included unsuccessful clinical trials going unreported, data being selectively reported in major journals, information not released to the public when it was available to the FDA, and drugs being put on (and in at least the case of Vioxx taken off) the market without full disclosure of the dangers that were known to the manufacturers. Furthermore the blame for all this is shared between pharma, the FDA and the main medical journals. There may be good reasons for keeping potentially dangerous drugs available for physicians to prescribe (see Sydney’s sensible view in the last paragraph of this post at Medpundit). But I urge you to read John Abramson’s Overdosed America which demonstrates how poorly the information that’s known about the use of drugs and other therapies is presented to the public and the medical profession. Even with the domination of all branches of government by the Republicans, it’s unlikely that nothing significant will be done to the FDA. Look for the bolstering of the post-market surveillance function, and also for an enhancement of the clinical trials.gov site as better reporting of all trials is demanded by governments internationally. However, we’re not ready for an American NICE just yet.

Medicare “Modernization” (or NAIM as Jeanne Scott calls it or TEOMAWKI as I called it after Ross wrote about it–prizes for those figuring out the acronyms). There is going to be a great deal of mind-numbing details to be sorted out in 2005 regarding how much of what’s happening in Medicare this year and next will work. Five quick ones are:

  • How the Part D private drug benefit plans are going to be developed, marketed and chosen, and what they’re going to have to include in their formularies, and how much lee-way they’ll have to negotiate with pharma
  • How (and if) the new Medicare Advantage PPOs are going to work cross-state-borders.
  • Will the Medicare Advantage HMOs grow as fast as Wall Street thinks they will with the new money going to the plans?
  • What will be the real progress of the Medicare CCIP disease management programs? This will be the focus of disease management wonks for the next 24 months.
  • Everyone involved in the business of injectable drugs for oncology, ESRD, etc paid for by Medicare Part B will continue to scramble to figure out what’s really going to happen and what “ASP plus 6%” really means.

My impression is that the next 2-3 years will see slightly slower transformation of Medicare than the hype would have us believe. Most seniors will stick with their current drug coverage, and employers will be relatively reluctant to dump their retirees from Medigap coverage immediately. Most seniors will be somewhat reticent to go back into the HMOs which dumped them a few years back. And eventually the Congress will notice that paying private plans more for something the main Medicare program can deliver cheaper is not great business in a time of ever largening deficits. So I’m not among those thinking that the traditional Medicare program will be gone in a few years. But for those of you in the business there is a lot of work to be done figuring out the details of these new programs.

Pharma Marketing Reform: I don’t think that the FDA will ban DTC advertising quite yet, and I don’t think that the current Congress will get too involved in regulation of pharma marketing. But I do think that the slow changes seen last year in the way that big pharma itself does its sales and marketing will become more obvious. Results are starting to come in that some of this electronic detailing and other approaches to marketing are more cost-effective than sending out reps. Sales teams are the biggest empires in big pharma, and big empires only change in times of stress. But stress in the form of some big patent expiries and some unexpected pulls of drugs from the market–and the associated decrease in revenue–is on the way (or already here in Merck’s case). Despite all the money spent on data and sales force automation, there is room for a lot more efficiency in this area. Expect pharma to grapple with making their sales forces smaller, more effective at physician targeting, and less willing to use the technique of throwing vast quantities of mud at the wall and hoping that some of it sticks.

Medical Errors: Michael Millenson will continue to write articles about how appallingly slow the response by the health care system and medical profession has been in responding to the crisis. The current slow rate of CPOE installation will pick up the pace oh-so-slightly, and going to the hospital in the US (and the UK) will remain a somewhat dangerous endeavor. Congress will do, effectively, nothing. (Yes that’s an actual real-life prediction).

Malpractice: Medrants’ comments section will continue to be filled with dueling doctors and trial lawyers and, barring any new national emergency distracting their attention, the Repubs in the Senate will make a run at instituting a national cap on pain and suffering damages. If they pull the nuclear option of changing the Senate rules in order to get some of Bush’s wackier nut-job nominations through for the Federal bench, then malpractice “reform” might get through too. But even if it passes physicians will quickly figure out that they got it wrong; damages caps don’t help them too much. Instead they should have gone for a real system-changing compromise while they had the chance. But as that would involve giving something up (such as the admission that doctors should be held accountable to national best practices), there’s no way the AMA will allow it.

Consumers, HSAs, CDHPs and all that: The fuss about consultant-directed health plans will continue to grow and their role in the individual insurance market will expand somewhat. I still don’t think that they’ve really got too much chance of being a major force in the employer based-insurance market once VPs of HR start being able to do basic math. However, health plans and banks will slowly get it together on offering integrated products that actually work for consumers. Most important for providers is whether the typical CDHP (or high-deductible plan) comes with a PPO attached as most do now. In that case claims will be routed through the health plans and all the hopes physicians have been holding all these years of the simplicity of direct payment from consumers will be dashed, as the consumer waits for their EOB and gets as confused about it as they do now. Plus they’ll get (or at least see) the discounted rate and won’t want to pay more. I think this is the likely future of HSAs — it’s how mine works– and I foresee physicians being very disappointed by their impact. I also foresee my inbox being filled with missives from ideological libertarians who don’t understand health care and fruitcake insurance salesmen. Oh, and customer service from health plans will continue to suck.

Quality: We may, just, be at the start of some public awareness about quality issues in health care. Obviously Vioxx is part of that, but I also picked up some discussion of quality in more mainstream publications, including in the NY Times Editorial for resolutions for 2005. This is a sleeper issue that may well stay asleep forever, but perhaps something could bring it closer to the forefront, and my hope is that something is a Nobel Prize for Jack Wennberg.

Information Technology: Now we’ve all sung Kum-ba-ya and got the T-shirt, we will return to our caves and notice that David Brailer believes that interoperability (or at least seamless transfer of data) is the reason for making all these vast IT investments. We’ll then also notice that even Brailer says that there are no business reasons for anyone in health care to make their systems inter-operable, and that there won’t be any government regulation forcing them to do so. Then we’ll further notice that Brailer’s office didn’t get funded by Congress and he’ll have to pass the hat around at HHS to buy his staff sandwiches (and pay them); whereas the Brits are putting $20 billion into their IT initiative (and BTW believe it or not are giving Halliburton a job as a watchdog on how the money is spent…yes, that Halliburton!). However, the good news is that some of the bigger private systems, like the Kaisers and the Sutters, will forge ahead with their initiatives but the vast majority of American patients and doctors won’t notice the difference for several more years. The EMR will remain 3-5 years into the future, but it won’t necessarily stay that way forever. (There you go, how about that for a hint of forecasting optimism!)

Specialty Hospitals: A big fight is coming up concerning the end of the moratorium on specialty hospitals. My guess is that the moratorium ends and that hospitals get heavily involved in doing whatever it takes to placate their superstar surgeons, which probably means most of them joint-venturing with them on new facilities. The “haves” versus “have-nots” divide will be exacerbated.

Policy: The Bushies will have a run at promoting the Federalization of AHPs. I suspect that they’ll fail given the strength of the Blues, and the limited capital Bush will have for this. But it’s a new full employment act for insurance fraud if they succeed!

The uninsured: Will continue to be turned back at the Canadian border. If you’re uninsured there’s no hope for significant change this year. But this issue combined with the cost issue will fester away until some Democrat picks it for their 2008 topic and tries to go after Bush’s middle class support with it.

Wildcards: These events probably won’t happen, but if they do it’ll be a big deal

  • A major implantable medical device gets recalled, as in needs to be removed from everyone it’s inside of
  • Avian flu crosses over and public health systems virtually collapse
  • A class action suit against big pharma takes on the anti-tobacco suit properties and dominates the industry.
  • The terms of Medicare Drug coverage are so good that almost all seniors join it
  • Some Republicans develop a conscience and we get a Congressional opposition to many of the wackier Bush plans.

Blogs: If 2004 was the year of the political blog, 2005 might begin to be the year of mainstreaming of business blogs. My forecast is that bloggers will try to figure out how to make money at this, but that most of them will fail at that (and sadly their numbers will probably include me!)

Soccer: Chelsea will finally win the league after 50 years. OK that’s a fervent hope, but we’re 5 points clear and looking good!

PERSONAL: My end of year letter

Happy New Year and Welcome to 2005! Every year I put out an email to my friends and family about what I’ve been up to, and what charities and causes I’m supporting. If you’d like to read it, it’s posted on my personal blog here.

THCB Media Packet

Want to reach a weekly audience of thousands of health care industry insiders and watchers? THCB is read by more than a thousand visitors a day, including industry analysts, physicians, investors, Wall Street insiders and executives from every top health system in the country.

Advertise with us and you’ll put your brand in front of a smart & tightly focused demographic, one at the forefront of an evolving marketplace.

From start-ups to new studies

THCB covers the health care spectrum,  providing commentary and insight on industry news, interviews with industry leaders and commentary from some of the top minds in the field. We write about the top new companies in the field, important trends and the issues health care professionals are talking about. Including:

> Hospitals & insurers> Physicians> Health care information technology
> Health policy
> Medical devices
> Electronic medical records
> The pharmaceutical industry
> Regulation and economic issues

Getting Started

Getting started is easy. Just select an ad format and length of run from the list of options below. Then send us a copy of the ad you would like to run together with the web address you would like the spot to link to. In most cases approvals take under 24 hours. Paying is just as easy. We accept Paypal and corporate check. Questions? Email jo**@***************og.com

Advertising Options

Above the
fold

This
prominent placement puts your ad in a can’t miss-spot certain to catch readers
attention: centered in the main sidebar beneath our search feature. Options include box and skyscraper
formats. Your spot will be shown on every page on the site using our main template. (2,000 plus pages.)

Inline

This
approach delivers your message directly in the flow of content between
posts, guaranteeing
maximum exposure. A text box or graphic is placed directly between
spots. We’ll track click through and other data for you.

Text Message
This is a good option for getting word out quickly to the health care industry about a new
product or service. You’ll give us a five line text advert that runs
between posts. (Think of an online format similar to that of the traditional
newspaper classified.) 

Sponsored Links

Good for building exposure for your brand or web site. Places your targeted link in a prominent location in the right sidebar. A limited number of spots are available. Act quickly to reserve yours for 2007. (2 available)

THCB Update

The THCB Update e-mail goes out three to five times a week to an audience of 900 regular readers. Catch the eye of some of the smartest people in the health care industry, including industry observers, Wall Street people and executives at the top health care systems and physician group practices in the country. Email jo**@***************og.com for more info.

Custom Package

We are
happy to work with you to create a specialized content section or other
promotional package emphasizing your brand and targeting a specific sector.

THCBs Greatest Hits

THIS IS A BRIEF COLLECTION of twenty-five posts written for THCB in the nearly two years since I started this project .  You’ll find essays on a wide range of topics in health care policy and health care economics.  You may want to try reading them through end to end (probably ambitious) or you may want to dip in for a quick browse around and then come back later for more.  I’ll update this list with more later when I get a chance. If there is a post you’d particularly like to see here, you can add a comment with your suggestion at the bottom of the page. Cheers! — Matthew

Oh Canada
http://matthewholt.typepad.com/the_health_care_blog/2003/11/policy_oh_canad_1.html

Letter from England
http://matthewholt.typepad.com/the_health_care_blog/2004/01/quality_quickie.htmlIt’s a good year for the Rowe(s)
http://matthewholt.typepad.com/the_health_care_blog/2004/03/health_plans_it.htmlWhy is the individual market such a mess?
 http://matthewholt.typepad.com/the_health_care_blog/2003/12/health_planspol_1.html

Michael Porter sinking into the Healthcare Quaqmire
 http://matthewholt.typepad.com/the_health_care_blog/2004/09/policyhealth_pl_1.html

As you may have guessed CDHP = cost shifting
http://matthewholt.typepad.com/the_health_care_blog/2004/04/health_plans_as.html

For Profits cost more but that’s not the point
 http://matthewholt.typepad.com/the_health_care_blog/2004/06/hospitalspolicy.html

The value of healthcare–interesting issue but appalling analysis
http://matthewholt.typepad.com/the_health_care_blog/2004/01/policyindustry_.html

Why Wall Street hates health care services but doesn’t know it
http://matthewholt.typepad.com/the_health_care_blog/2003/09/why_wall_street.html

PHARMA: The New Yorker, Industry Veteran and Atlas on pharma pricing and
where the industry goes next.
http://matthewholt.typepad.com/the_health_care_blog/2004/10/pharma_the_emne.html

The Real Debate behind Reimportation
http://matthewholt.typepad.com/the_health_care_blog/2004/09/pharma_the_real.html

Drug prices here and there
http://matthewholt.typepad.com/the_health_care_blog/2004/03/pharma_drug_pri.htmlAre Cox-2s over used? http://matthewholt.typepad.com/the_health_care_blog/2003/11/pharmapbms_are_.html

Online detailing and perscribing–taking off at last?
http://matthewholt.typepad.com/the_health_care_blog/2003/08/online_detailin.html

Sorry! Got it all wrong–PBMs save money.
http://matthewholt.typepad.com/the_health_care_blog/2004/07/pbms_sorry_got_.html As I’ve always suspected, Health Care = Communism + Frappuccinos
http://matthewholt.typepad.com/the_health_care_blog/2005/01/policy_as_ive_a.html

Prop 72- Sorry couldn’t help myself
http://matthewholt.typepad.com/the_health_care_blog/2004/11/policypolitics_.html

Why dishonesty rules in our health care "debate"
http://matthewholt.typepad.com/the_health_care_blog/2004/10/policy_why_dish.html

"Producers" comment on how much we should spend on health care.
http://matthewholt.typepad.com/the_health_care_blog/2004/09/policypharma_pr.html International comparisons, or "How does Japan do it?" revisited
http://matthewholt.typepad.com/the_health_care_blog/2004/09/policy_internat.html

Toto, we’re back in Kansas and it’s 1991 again.
http://matthewholt.typepad.com/the_health_care_blog/2004/07/policy_toto_wer.html

Reggie’s back and the intellectual slop goes on
http://matthewholt.typepad.com/the_health_care_blog/2004/04/consumersindust.html

Health Care Costs 101 http://matthewholt.typepad.com/the_health_care_blog/2003/12/policy_health_c.html

User fees, employer-based insurance and why it won’t go away
http://matthewholt.typepad.com/the_health_care_blog/2003/10/policy_user_fee.html

Medicaid–a bleak picture gets bleaker
http://matthewholt.typepad.com/the_health_care_blog/2003/09/medicaida_bleak.html

Jeanne Scott looks at Single payer, MSAs and what employees want: I
editorialize back
http://matthewholt.typepad.com/the_health_care_blog/2003/09/jeanne_scott_lo.html

assetto corsa mods